中国防痨杂志
中國防癆雜誌
중국방로잡지
BULLETIN OF THE CHINESE ANTITUBERCULOSIS ASSOCIATION
2009年
8期
484-487
,共4页
结核%肺/外科学
結覈%肺/外科學
결핵%폐/외과학
Tuberculosis%pulmonary/surgery
目的 探讨当前肺结核病的外科治疗效果和手术适应症.方法 总结胸外科1999年1月-2007年12月手术切除的388例肺结核病的临床疗效.全组浸润肺结核116例,结核球或干酪性肺炎85例,慢性纤维空洞性肺结核66例,肺结核合并曲菌球形成18例,结核性支气管狭窄28例,结核性毁损肺75例.结果 全肺切除术95例,肺叶切除术217例,气管或支气管成形术11例,其他手术65例.外科切除临床治愈372例治愈率95.9%,并发症33例发生率为8.5%,手术无死亡.结论 虽然肺结核是以抗结核药物为主要治疗方法 ,但目前仍有部分患者需要外科治疗,外科手术可提高重症和耐多药肺结核的临床治愈率.
目的 探討噹前肺結覈病的外科治療效果和手術適應癥.方法 總結胸外科1999年1月-2007年12月手術切除的388例肺結覈病的臨床療效.全組浸潤肺結覈116例,結覈毬或榦酪性肺炎85例,慢性纖維空洞性肺結覈66例,肺結覈閤併麯菌毬形成18例,結覈性支氣管狹窄28例,結覈性燬損肺75例.結果 全肺切除術95例,肺葉切除術217例,氣管或支氣管成形術11例,其他手術65例.外科切除臨床治愈372例治愈率95.9%,併髮癥33例髮生率為8.5%,手術無死亡.結論 雖然肺結覈是以抗結覈藥物為主要治療方法 ,但目前仍有部分患者需要外科治療,外科手術可提高重癥和耐多藥肺結覈的臨床治愈率.
목적 탐토당전폐결핵병적외과치료효과화수술괄응증.방법 총결흉외과1999년1월-2007년12월수술절제적388례폐결핵병적림상료효.전조침윤폐결핵116례,결핵구혹간락성폐염85례,만성섬유공동성폐결핵66례,폐결핵합병곡균구형성18례,결핵성지기관협착28례,결핵성훼손폐75례.결과 전폐절제술95례,폐협절제술217례,기관혹지기관성형술11례,기타수술65례.외과절제림상치유372례치유솔95.9%,병발증33례발생솔위8.5%,수술무사망.결론 수연폐결핵시이항결핵약물위주요치료방법 ,단목전잉유부분환자수요외과치료,외과수술가제고중증화내다약폐결핵적림상치유솔.
Objective To evaluate the efficacy and indication of surgical resection for pulmonary tuberculosis. Methods From January 1999 to December 2007, 388 patients with pulmonary tuber-culosis hospitalized in our hospital undergone surgical resection were enrolled. There were 116 cases with infiltrative pulmonary tuberculosis,85 cases with caseous pneumonia, 66 cases with chronic fi-bro-cavernous pulmonary tuberculosis, 18 cases pulmonary tuberculosis complicated with aspergillo-ma,28 cases with tuberculous tracheobronchial stenosis,75 cases with tuberculous destroyed lungs. Results The operative manners included: pneumonectomy in 95 cases, lobectomy in 217, tracheo-plasty or bronchoplasty in 11 cases, and other manners in 65 cases. The total cure rate was 96% a-mong 372 cases treated by operation. The rate of complication was 8. 5% without dead case. Con-clusions Chemotherapy is still main method to treat pulmonary tuberculosis,but the surgical opera-tion is necessary for some patients with pulmonary tuberculosis to improve cure rate, especially for severe pulmonary tuberculosis and multidrug-resistant tuberculosis(MDR-TB).